Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Goldman names 2 ASX healthcare shares to buy
Goldman Sachs names 3 ASX healthcare shares to buy
Small Cap Shares
7 small-cap ASX shares that have been oversold: Wilsons
Why ASX, Coronado, Graincorp, and Integral Diagnostics shares are dropping today
2 ASX shares to buy now at bargain prices that you’ve forgotten about
Is opportunity knocking? 2 ASX All Ordinaries shares hitting 52-week lows
Integral Diagnostics (ASX:IDX) share price on ice after trio of big announcements
Ask a Fund Manager
2 ASX shares to buy for dirt cheap right now: expert
|01 Mar 2022||$0.0400||100.00%||Interim||04 Apr 2022|
|02 Sep 2021||$0.0700||100.00%||Final||06 Oct 2021|
|01 Mar 2021||$0.0550||100.00%||Interim||06 Apr 2021|
|28 Aug 2020||$0.0400||100.00%||Final||01 Oct 2020|
|28 Feb 2020||$0.0550||100.00%||Interim||07 Apr 2020|
|30 Aug 2019||$0.0500||100.00%||Final||02 Oct 2019|
|01 Mar 2019||$0.0500||100.00%||Interim||02 Apr 2019|
|31 Aug 2018||$0.0400||100.00%||Final||04 Oct 2018|
|31 Jan 2018||$0.0400||100.00%||Interim||05 Mar 2018|
|31 Aug 2017||$0.0400||100.00%||Final||04 Oct 2017|
|28 Feb 2017||$0.0300||100.00%||Interim||30 Mar 2017|
|31 Aug 2016||$0.0400||100.00%||Final||04 Oct 2016|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Integral Diagnostics Ltd is an Australian healthcare services company. The group operates in a single business. It provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients.
|12 Aug 2022||$3.17||$-0.03||-0.94%||472,524||$3.15||$3.21||$3.12|
|11 Aug 2022||$3.20||$0.09||2.89%||653,348||$3.20||$3.24||$3.16|
|10 Aug 2022||$3.11||$-0.11||-3.42%||354,233||$3.24||$3.24||$3.11|
|09 Aug 2022||$3.22||$-0.05||-1.53%||232,926||$3.34||$3.34||$3.21|
|08 Aug 2022||$3.27||$-0.09||-2.68%||883,430||$3.35||$3.39||$3.27|
|05 Aug 2022||$3.36||$0.10||3.07%||634,428||$3.27||$3.37||$3.26|
|04 Aug 2022||$3.26||$0.09||2.84%||722,470||$3.20||$3.29||$3.19|
|03 Aug 2022||$3.17||$-0.15||-4.52%||752,935||$3.32||$3.32||$3.17|
|02 Aug 2022||$3.32||$0.10||3.11%||854,806||$3.25||$3.33||$3.22|
|01 Aug 2022||$3.22||$0.13||4.21%||580,264||$3.14||$3.24||$3.14|
|29 Jul 2022||$3.09||$0.06||1.98%||798,283||$2.90||$3.09||$2.90|
|28 Jul 2022||$3.03||$0.19||6.69%||851,428||$2.93||$3.06||$2.84|
|27 Jul 2022||$2.84||$0.08||2.90%||2,366,722||$2.42||$2.89||$2.38|
|26 Jul 2022||$2.76||$-0.09||-3.16%||1,002,363||$2.85||$2.85||$2.71|
|25 Jul 2022||$2.85||$-0.09||-3.06%||390,398||$2.93||$2.94||$2.84|
|22 Jul 2022||$2.94||$0.05||1.73%||1,131,343||$2.90||$2.96||$2.88|
|21 Jul 2022||$2.89||$0.00||0.00%||1,446,497||$2.88||$2.91||$2.82|
|20 Jul 2022||$2.89||$-0.05||-1.70%||666,759||$2.95||$3.00||$2.87|
|19 Jul 2022||$2.94||$-0.01||-0.34%||558,230||$2.97||$2.99||$2.94|
|18 Jul 2022||$2.95||$0.10||3.51%||450,243||$2.90||$2.97||$2.86|
|15 Jul 2022||$2.85||$-0.11||-3.72%||361,807||$2.95||$2.95||$2.85|
|14 Jul 2022||$2.96||$-0.03||-1.00%||447,863||$3.02||$3.02||$2.95|
|04 Apr 2022||John Atkin||Issued||1||$6,449|| |
Dividend Reinvestment Plan (DRP).
|22 Mar 2022||John Atkin||Issued||20||$71,576|| |
|22 Mar 2022||Ian Kadish||Issued||87||$300,920|| |
|28 Feb 2022||Jacqueline Milne||Buy||19||$69,650|| |
|22 Feb 2022||Helen Kurincic||Issued||63||$218,422|| |
|08 Nov 2021||Ian Kadish||Issued||157||$775,839|| |
Issue of securities. 777,559 - Performance Rights
|06 Oct 2021||John Atkin||Issued||2||$11,124|| |
Dividend Reinvestment Plan (DRP).
|06 Oct 2021||Rupert Harrington||Issued||3||$14,797|| |
Dividend Reinvestment Plan (DRP).
|06 Oct 2021||Rupert Harrington||Issued||2||$10,228|| |
Dividend Reinvestment Plan (DRP).
|31 Aug 2021||Ian Kadish||Buy||362||$1,675,142|| |
Conversion of securities.
|31 Aug 2021||Ian Kadish||Exercise||362||$1,675,142|| |
Conversion of securities. 620,188 - Rights
As per announcement on 01/09/2021
|Mr Andrew James Fay||Non-Executive Director||Jul 2022|| |
Mr Fay has over 30 years of experience in the financial services industry, having knowledge of investment and funds management. His executive experience included Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited and has provided corporate strategic advice across diverse industries. Mr Fay has experience as a company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, strategy, executive remuneration frameworks, investment and corporate governance. He is currently a non-executive director of National Cardiac Pty Ltd and formerly a nonexecutive director of numerous entities including Pendal Group Ltd (ASX:PDL), Spark Infrastructure RE Limited (ASX:SKI), Cromwell Property Group (ASX:CMW), JO Hambro Capital Management Holdings Ltd, South Australian and Victorian Power Networks, Gateway Lifestyle Group and Chair of Deutsche Managed Investments Ltd. He is also a Member of the Risk & Compliance Committee, Member of the People, Culture Committee and Chair the Mergers and Acquisitions Working Group.
|Dr Jacqueline Milne||Executive Director||Nov 2019|| |
Dr Milne began her medical career as a practicing radiographer at South Coast Radiology prior to commencing her medical degree and radiology qualifications. The multidisciplinary experience Dr Milne brings as both a radiographer and radiologist to the Board is invaluable. Dr Milne's specialty interests include women's imaging, medical training and general procedural work. Dr Milne is also an active member of the IDX Queensland radiologist group being a member of the Queensland Clinical Leadership Committee.
|Ms Raelene Margaret Murphy||Non-Executive Director||Oct 2017|| |
Ms Murphy has over 30 years experience in strategic, financial and operational leadership in both industry and professional advisory after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career she specialised in operational and financial restructuring with a particular emphasis on merger and acquisition integration across a range of significant public and private companies. Ms Murphy is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX Listed companies. She is currently a Non-Executive Director of ASX listed Altium Limited (ASX:ALU), Bega Limited (ASX:BGA) and Elders Limited (ASX:ELD).
|Ms Helen Kurincic||Non-Executive ChairmanNon-Executive Director||Dec 2014|| |
Ms Kurincic has Executive and Board-level experience across the healthcare industry. Previously, Ms Kurincic was the Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first and largest radiation oncology and cardiology business across Australia. Prior to that, Ms Kurincic held various Executive and Non-Executive healthcare sector roles including Non-Executive Director of DCA Group Ltd (diagnostic imaging services in Australia and the United Kingdom), Non-Executive Director of AMP Capital Investors Domain Principal Group, CEO of Benetas and NonExecutive Director of Melbourne Health and Orygen Research Centre. Ms Kurincic has also been actively involved in healthcare government policy reform including appointments by health ministers as Chair of the Professional Programs and Services Committee for the Fourth Community Pharmacy Agreement and Member of the Minister's Implementation Taskforce and Minister's Reference Group for the Long Term Reform of Aged Care. She is currently the Independent Non-Executive Chair of McMillian Shakespeare Limited (ASX:MMS), a Non-Executive Director of Estia Health Limited (ASX:EHE), HBF Health Limited, and the Victorian Clinical Genetics Service. She is also a senior advisor in the healthcare sector.
|Mr John Atkin||Non-Executive Director||Oct 2015|| |
Mr Atkins is an experienced company director and in 2018, Mr Atkins was appointed Chair of the Australian Institute of Company Directors. Mr Atkins was Chief Executive Officer and Managing Director of The Trust Company Limited from 2009 to 2013 prior to its successful merger with Perpetual Limited. Prior to joining the Trust Company, Mr Atkins was the managing partner and Chief Executive Officer of leading Australasian law firm Blake Dawson (now Ashurst). Before this, Mr Atkins was a senior mergers and acquisitions partner of Mallesons Stephen Jaques (now King & Wood Mallesons). He is currently a Non-Executive Director of IPH Limited (ASX:IPH). Mr Atkins is also a director of a number of unlisted entities including Qantas Superannuation Limited, trustee of the Qantas Superannuation Fund and Outward Bound International Inc.
|Dr Ian Kadish||Chief Executive OfficerManaging Director||May 2017|| |
Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. He had several roles overseas including with McKinsey and Company, CSC Healthcare in New York City, and Netcare, a major hospital group in South Africa and the United Kingdom, where Dr Kadish was an Executive Director from 1997 to 2006. Mr Kadish was instrumental in growing the group from five hospitals with a market capitalisation of $60 million, to 119 hospitals and a market capitalisation of $3 billion. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group (previously ASXlisted hospital group) and CEO of Laverty Pathology. Mr Kadish is also a Non-Executive Director of Teaminvest Private Group Limited (ASX:TIP).
|Dr Nazar Bokani||Executive Director||Apr 2021|| |
Besides general radiological and interventional work Dr Bokani covers cross-sectional CT & MRI work, Cardiac CT, Ultrasound and symptomatic breast sessions both diagnostic and interventional. Dr Bokani is also an active member of the IDX Western Australian radiologist group being a member of the Western Australian Clinical Leadership Committee.
|Ms Kirsty Lally||Company Secretary||Jul 2019|| |
|Anne Lockwood||Chief Financial and Commercial Officer|| |
|Paul McCrow||Chief Operating Officer|| |
|Kirsty Lally||Company Secretary|| |
|J P Morgan Nominees Australia Pty Limited||35,091,908||17.67%|
|HSBC Custody Nominees (Australia) Limited||24,201,530||12.18%|
|Citicorp Nominees Pty Limited||19,851,055||9.99%|
|National Nominees Limited||11,501,438||5.79%|
|BNP Paribas Noms Pty Ltd <Drp>||7,248,733||3.65%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp>||3,831,101||1.93%|
|Peter J Ansley + St Leger M Reeves + Stephen Eichsteadt + Thomas Q St Leger||3,747,786||1.89%|
|Reeves <Magnolia A/C>||3,108,210||1.56%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||3,001,725||1.51%|
|New Imaging Pty Ltd <New Imaging A/C>||2,467,230||1.24%|
|Lethean Holdings Pty Ltd <Howitt No 8 A/C>||2,357,230||1.19%|
|Firbar Pty Ltd <The Howitt No 4 A/C>||2,293,174||1.15%|
|Wyndham Salter Pty Ltd <The Howitt No 10 A/C>||2,128,000||1.07%|
|Mr Vincent Michael O'Sullivan <O'Sullivan A/C>||2,085,907||1.05%|
|Mittal Holdings Pty Ltd <Howitt No 12 A/C>||2,080,133||1.05%|
|Lockwood Ridge Pty Ltd <The Aj French Family A/C>||2,074,375||1.04%|
|Nw3 Pty Ltd <The Howitt No 7 A/C>||1,806,118||0.91%|
|HSBC Custody Nominees (Australia) Limited <Nt - Comnwlth Super Corp A/C>||1,654,326||0.83%|
|Citicorp Nominees Pty Limited <Colonial First State Inv A/C>||1,617,402||0.81%|
|Willowbay Rise Pty Ltd <Howitt No 5 A/C>||1,484,961||0.75%|